SCHEDULE: Orca Capital AG Discloses 4.9% Stake in Purple Biotech

Orca Capital AG has reported a 4.9% beneficial ownership in Purple Biotech Ltd. through American Depositary Shares, adhering to a 4.99% ownership blocker on its Series B warrants.

Summary

• Orca Capital AG beneficially owns 306,394 American Depositary Shares (ADSs) of Purple Biotech Ltd.
• This ownership represents 4.9% of the class of securities.
• The ownership percentage is calculated based on 6,085,450 ADSs outstanding immediately after Purple Biotech's registered offering.
• Orca Capital AG also holds 1,832,495 ADSs issuable upon the exercise of Series B warrants.
• A 4.99% blocker prevents Orca Capital AG from exercising warrants if it would result in beneficial ownership exceeding 4.99% of Purple Biotech's outstanding Ordinary Shares, including those represented by ADSs.
• The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It confirms a significant institutional investor's stake, which can be seen as a vote of confidence, but it's a passive investment with a clear ownership cap, limiting potential for active engagement or a larger stake from this specific investor.

Positives

• A significant institutional investor, Orca Capital AG, holds a substantial stake, indicating confidence in Purple Biotech Ltd.
• The 4.99% blocker demonstrates the investor's intent to remain a passive shareholder, which can be viewed positively by current management by reducing concerns about activist intervention.

Negatives

• The 4.99% blocker limits Orca Capital AG's ability to increase its stake beyond this threshold through warrant exercise, potentially capping its influence or future investment in the company.

Risks

• The 4.99% blocker on Series B warrants limits Orca Capital AG's ability to fully exercise its warrants and increase its ownership beyond the stated threshold, potentially impacting future capital deployment or strategic influence from this specific investor.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in the biotech sector, with investors like Orca Capital AG taking significant, albeit passive, stakes in companies such as Purple Biotech Ltd. The use of American Depositary Shares (ADSs) and warrants with ownership blockers is a common mechanism for international investors to gain exposure while managing regulatory thresholds and avoiding activist investor classifications.

Comparison to Industry Standards

• The 4.9% stake is a common threshold for passive institutional investors to report, often staying below the 5% mark to avoid more stringent reporting requirements (e.g., Schedule 13D) and potential regulatory scrutiny.
• The 4.99% blocker on warrant exercise is a standard provision used by companies to prevent an investor from inadvertently triggering beneficial ownership thresholds that could lead to a change of control or more extensive regulatory obligations.
• Many biotech companies, particularly those with international operations or listings, utilize American Depositary Shares (ADSs) to facilitate investment from U.S. and global investors, similar to Purple Biotech Ltd., enhancing liquidity and accessibility.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder. The passive nature (4.9% stake, 4.99% blocker) suggests stability without immediate control concerns.
• Management: Confirms a significant, but passive, institutional investor, which can be a positive signal without the pressure of an activist investor.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a passive ownership stake by Orca Capital AG. While the presence of an institutional investor is generally positive, the 4.9% stake and the 4.99% blocker on warrant exercise indicate a non-activist position. The filing does not provide new financial performance data or strategic shifts that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's fundamentals rather than this ownership disclosure.

Keywords

Purple Biotech Ltd., Orca Capital AG, Schedule 13G, American Depositary Shares, ADSs, Beneficial Ownership, Warrants, 4.99% Blocker, Biotech, Investment